Acinetobacter pneumonia is an infectious lung disease that is caused by the bacterium Acinetobacter baumannii. Therapeutics to treat Acinetobacter pneumonia aims at curing the infection and reducing associated symptoms. The increasing prevalence of hospital-acquired bacterial infections worldwide is a major driver for growth of this market. The market offers various antibiotic therapies as well as combination therapies for treatment of the disease.

The global Acinetobacter pneumonia therapeutics market is estimated to be valued at US$ 614.9 million in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the Global Acinetobacter Pneumonia Therapeutics Market Demand are Pfizer Inc., Merck & Co., Inc., GlaxoSmithKline plc (GSK), AstraZeneca plc, Novartis AG, Johnson & Johnson, Sanofi S.A., Bayer AG, and Basilea Pharmaceutical. These players are focusing on developing novel combination therapies through partnerships and collaborations to strengthen their product portfolio.

The rising prevalence of multi-drug resistant Acinetobacter baumannii infections globally present significant growth opportunities for players in this market. According to the Centers for Disease Control and Prevention, over two million people acquire antibiotic-resistant infections each year in the United States alone. Furthermore, growing healthcare infrastructure and expenditure in emerging economies of Asia Pacific and Latin America will aid market expansion in these regions over the forecast period.

Market Drivers and Restraints

One of the key drivers for growth of the global Acinetobacter pneumonia therapeutics market is the increasing number of hospitalizations annually which has led to a rise in hospital acquired infections. As per the World Health Organization, over 15% of hospitalized patients contract at least one healthcare associated infection globally each year. This has prompted research towards development of novel drugs and therapies for treatment of drug-resistant bacterial strains.

However, the market faces challenges in terms of high drug development and testing costs. Antibiotic resistance also poses a major threat as strains of Acinetobacter baumannii have shown resistance to almost all classes of antibiotics. Long duration of clinical trials further increases the overall costs involved in developing new treatment therapies. Stringent regulations delay market entry of new products to some extent. These factors may restrain market growth over the forecast period.

Segment Analysis

The global Acinetobacter pneumonia therapeutics market is dominated by the carbapenem segment due to high effectiveness against drug-resistant Acinetobacter infections. Carbapenems are a group of broad-spectrum beta-lactam antibiotics used to treat multidrug-resistant bacterial infections. They work by inhibiting cell wall synthesis in bacteria, which makes them effective against both gram-positive and gram-negative bacteria. The carbapenem segment accounted for over 35% market share in 2024 due to rising carbapenem resistance among Acinetobacter infections.

The aminoglycosides segment is the second largest sub-segment as they are commonly used to treat respiratory tract infections along with other drug classes. Aminoglycosides such as gentamicin, amikacin, and tobramycin are effective against most gram-negative bacteria including drug-resistant strains of Acinetobacter. However, increasing resistance to aminoglycosides is a restraining factor for the growth of this sub-segment.

Global Analysis

The North America region dominated the global Acinetobacter pneumonia therapeutics market in 2024 with over 45% market share. This is attributed to the rising prevalence of healthcare-associated infections (HAIs), growing elderly population susceptible to pneumonia, and availability of advanced treatment options in the region. The Asia Pacific region is projected to witness the highest CAGR during the forecast period. This is owing to improving healthcare infrastructure, increasing healthcare spending, and transforming pharmaceutical industry in emerging countries such as China and India. The growing population and unmet clinical needs also contribute to the market growth in the Asia Pacific region. The Europe market will grow moderately due to risk management policies, while regions such as Latin America and Middle East & Africa will provide growth opportunities due to expanding healthcare access in these markets.

Get more insights on Global Acinetobacter Pneumonia Therapeutics Market